ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results.

GlobeNewsWire • Feb 18, 2026

Niche Focus & Regulation Shape the Future of Healthcare Firms

CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.

Zacks Investment Research • Jan 15, 2026

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

Seeking Alpha • Jan 9, 2026

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.

GlobeNewsWire • Jan 8, 2026

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense ® product line and away from Re-Tain ® on December 24, 2025.

GlobeNewsWire • Jan 7, 2026

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain ® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense ® field sales force by 50% and expanding its First Defense ® manufacturing capabilities.

GlobeNewsWire • Dec 24, 2025

ImmuCell's Two-Product Edge in Cattle Health Fuels Growth

ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.

Zacks Investment Research • Dec 4, 2025

ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength

ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.

Zacks Investment Research • Nov 20, 2025

ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript

ImmuCell Corporation ( ICCC ) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Company Participants Michael Brigham - Special Advisor to the CEO & Director P. F. Te Boekhorst - President, CEO & Director Timothy Fiori - CFO, Secretary, Treasurer & Director Conference Call Participants Joe Diaz - Lytham Partners, LLC Frank Gasca George Melas - MKH Management Company, LLC Presentation Operator Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited Financial Results Conference Call.

Seeking Alpha • Nov 14, 2025

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025.

GlobeNewsWire • Nov 13, 2025